Australia’s Vaccine Value Chain Conference Outputs

There is an identified need in Australia’s Vaccine Value Chain to boost vaccine development, translation, commercialisation and access. Globally, there are urgent calls for international collaboration in epidemic and pandemic preparedness research from the World Health Organisation, and calls for critical reforms to the R&D ecosystem for infectious diseases from the Wellcome Trust. Responding to […]
Protected: Bringing Nuvaxovid™ to Market: A Novavax Case Study

There is no excerpt because this is a protected post.
HTA Roadmap For a New Vaccine in Australia

The landscape of vaccines in Australia is marked by stringent guidelines and a competitive marketplace and above all a focus on patient outcomes.
Biointelect partnered with a pharmaceutical company, well-versed in the Australian market but new to the vaccine domain, to develop a roadmap that would not only introduce their new vaccine but also potentially secure it a coveted position on the National Immunisation Program (NIP) with premium pricing.
Navigating European Market Access: A Strategic Blueprint for Novel Vaccines

Introduction The European medical market is the second-largest medical device market following the US, requiring newfound innovation for pharmaceutical companies to reach success. A US Biotech firm, on the cusp of introducing a groundbreaking first-in-class vaccine, sought Biointelect’s expertise to illuminate their path in this intricate and highly saturated market. With Biointelect’s strategic guidance and […]